EGFR and neoplasm: The prognostic importance of activating KRAS mutations extends beyond predicting sensitivity to anti-EGFR monoclonal antibodies, and may reflect a more migratory and invasive tumor biology resulting in early and frequent recurrences after hepatic resection.